Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Diabetic Foot Ulcers Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Diabetic Foot Ulcers Overview | 12 | 1 |
| Pipeline Products for Diabetic Foot Ulcers Comparative Analysis | 13 | 1 |
| Diabetic Foot Ulcers Therapeutics under Development by Companies | 14 | 2 |
| Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Diabetic Foot Ulcers Pipeline Products Glance | 17 | 4 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Unknown Stage Products | 20 | 1 |
| Diabetic Foot Ulcers Products under Development by Companies | 21 | 3 |
| Diabetic Foot Ulcers Products under Investigation by Universities/Institutes | 24 | 1 |
| Diabetic Foot Ulcers Companies Involved in Therapeutics Development | 25 | 28 |
| ANP Technologies Inc | 25 | 1 |
| CardioVascular BioTherapeutics Inc | 26 | 1 |
| Celgene Corp | 27 | 1 |
| Chrysalis BioTherapeutics Inc | 28 | 1 |
| CytoTools AG | 29 | 1 |
| EyeGene Inc | 30 | 1 |
| FirstString Research Inc | 31 | 1 |
| Genentech Inc | 32 | 1 |
| GlaxoSmithKline Plc | 33 | 1 |
| Human Stem Cells Institute | 34 | 1 |
| Izun Pharmaceuticals Corp | 35 | 1 |
| Karyopharm Therapeutics Inc | 36 | 1 |
| Lakewood-Amedex Inc | 37 | 1 |
| Lytix Biopharma AS | 38 | 1 |
| Mallinckrodt Plc | 39 | 1 |
| MediWound Ltd | 40 | 1 |
| NovaLead Pharma Pvt Ltd | 41 | 1 |
| Oneness Biotech Co Ltd | 42 | 1 |
| Osiris Therapeutics Inc | 43 | 1 |
| Pherecydes Pharma SA | 44 | 1 |
| Plurogen Therapeutics Inc | 45 | 1 |
| TechnoPhage SA | 46 | 1 |
| TGV-Laboratories | 47 | 1 |
| Theravasc Inc | 48 | 1 |
| Topadur Pharma AG | 49 | 1 |
| USV Pvt Ltd | 50 | 1 |
| viDA Therapeutics Inc | 51 | 1 |
| ViroMed Co Ltd | 52 | 1 |
| Diabetic Foot Ulcers Therapeutics Assessment | 53 | 9 |
| Assessment by Monotherapy Products | 53 | 1 |
| Assessment by Target | 54 | 2 |
| Assessment by Mechanism of Action | 56 | 2 |
| Assessment by Route of Administration | 58 | 2 |
| Assessment by Molecule Type | 60 | 2 |
| Drug Profiles | 62 | 80 |
| 3K3A-APC Drug Profile | 62 | 2 |
| ALLO-ASC Drug Profile | 64 | 1 |
| ANP-017 Drug Profile | 65 | 1 |
| AP-102 Drug Profile | 66 | 1 |
| APO-2 Drug Profile | 67 | 1 |
| becaplermin biosimilar Drug Profile | 68 | 1 |
| Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer Drug Profile | 69 | 2 |
| Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers Drug Profile | 71 | 1 |
| CL-05 Drug Profile | 72 | 3 |
| CODA-001 Drug Profile | 75 | 2 |
| CVBT-141B Drug Profile | 77 | 1 |
| Cyndacel-M Drug Profile | 78 | 1 |
| daprodustat Drug Profile | 79 | 2 |
| EG-Decorin Drug Profile | 81 | 1 |
| epidermal growth factor biosimilar Drug Profile | 82 | 1 |
| EscharEx Drug Profile | 83 | 2 |
| esmolol hydrochloride Drug Profile | 85 | 1 |
| Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers Drug Profile | 86 | 1 |
| Granexin Drug Profile | 87 | 2 |
| Heberprot-P Drug Profile | 89 | 1 |
| IMSP-001 Drug Profile | 90 | 1 |
| IZN-6D4 Drug Profile | 91 | 1 |
| LTX-109 Drug Profile | 92 | 2 |
| MT-003 Drug Profile | 94 | 1 |
| Mul-1867 Drug Profile | 95 | 1 |
| Neovasculgen Drug Profile | 96 | 1 |
| Nu-2 Drug Profile | 97 | 1 |
| Nu-3 Drug Profile | 98 | 2 |
| ON-101 Drug Profile | 100 | 2 |
| OTI-1501 Drug Profile | 102 | 1 |
| PDA-002 Drug Profile | 103 | 1 |
| PluroGel N Drug Profile | 104 | 1 |
| PP-2351 Drug Profile | 105 | 1 |
| Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers Drug Profile | 106 | 1 |
| RG-7880 Drug Profile | 107 | 1 |
| rusalatide acetate Drug Profile | 108 | 3 |
| selinexor Drug Profile | 111 | 19 |
| sodium nitrite SR Drug Profile | 130 | 2 |
| Stathmin-1 Drug Profile | 132 | 1 |
| TOPN-53 Drug Profile | 133 | 1 |
| TP-102 Drug Profile | 134 | 1 |
| V-10 Drug Profile | 135 | 1 |
| VM-202 Drug Profile | 136 | 4 |
| VTI-1000 Series Drug Profile | 140 | 1 |
| VTI-3000 Series Drug Profile | 141 | 1 |
| Diabetic Foot Ulcers Dormant Projects | 142 | 4 |
| Diabetic Foot Ulcers Discontinued Products | 146 | 1 |
| Diabetic Foot Ulcers Product Development Milestones | 147 | 9 |
| Featured News &Press Releases | 147 | 1 |
| Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016 | 147 | 1 |
| Jul 19, 2016: The New Drugs ON101 (WH-1) of Oneness Biotech Meet the Phase III Clinical Trials Interim Requirement and is going to initiate Phase III Clinical Trials in China and EU | 147 | 1 |
| Jul 19, 2016: The New Drugs ON101 (WH-1) of Oneness Biotech Successively Pass the Blind Test | 147 | 1 |
| Jul 18, 2016: The Oneness Biotech Announce the Phase III Clinical Trials Results | 148 | 1 |
| Jul 18, 2016: The Worlds Best New Drugs Healing Rate of Oneness Biotech Is Accelerating Product Launch | 148 | 1 |
| Feb 02, 2016: MediWound EscharEx Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds | 148 | 2 |
| Jan 05, 2016: Izun Pharmaceuticals to Present at Biotech Showcase 2016 | 150 | 1 |
| Oct 13, 2015: Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers | 150 | 1 |
| Oct 06, 2015: Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds | 151 | 1 |
| Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer | 152 | 1 |
| Jul 31, 2015: Oneness Biotechs Investigational New Drug ON101 for Treating Chronic Diabetic Foot Ulcers Approved for SBIR grant program by Ministry of Economy Affairs | 153 | 1 |
| Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results | 154 | 1 |
| Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications | 154 | 1 |
| Jan 22, 2015: Oneness Biotech s Investigational New Drug ON101 Approved for Clinical Pharmacokinetic Studies by Ministry of Health and Welfare | 155 | 1 |
| Dec 03, 2014: Oneness Biotech s New Drug ON101 for Treatment of Chronic Diabetic Foot Ulcers Approved for Phase III Human Clinical Trials by Hong Kong Department of Health | 155 | 1 |
| Appendix | 156 | 2 |
| Methodology | 156 | 1 |
| Coverage | 156 | 1 |
| Secondary Research | 156 | 1 |
| Primary Research | 156 | 1 |
| Expert Panel Validation | 156 | 1 |
| Contact Us | 156 | 1 |
| Disclaimer | 157 | 1 |